Kateryna Krytska

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

Scott C. Bresler, Daniel A. Weiser, Peter J. Huwe et al. · Cancer Cell · 2014 · 383 citations · Full text

Medicine, Receptor Tyrosine Kinase, Pathology +4

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Nicole R. Infarinato, Jin H. Park, Kateryna Krytska et al. · Cancer Discovery · 2015 · 180 citations · Full text

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

Jo Lynne Rokita, Komal S. Rathi, Maria Cardenas et al. · Cell Reports · 2019 · 160 citations · Full text

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

Jungoh Ham, Carlotta Costa, Renata Sano et al. · Cancer Cell · 2016 · 130 citations · Full text

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb et al. · Clinical Cancer Research · 2021 · 117 citations · Full text